HIV-1 entry inhibitors: recent development and clinical use - Wikidata - wikimedia - TriplyDB

HIV-1 entry inhibitors: recent development and clinical use

HIV-1 entry inhibitors: recent development and clinical use

http://www.wikidata.org/entity/Q27003887

about

Approved Antiviral Drugs over the Past 50 Years Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening Peptide and protein-based inhibitors of HIV-1 co-receptors Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor.Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD.The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection.Evolution of coreceptor utilization to escape CCR5 antagonist therapy.Broad-spectrum antivirals against viral fusion.Short Communication: Inhibition of DC-SIGN-Mediated HIV-1 Infection by Complementary Actions of Dendritic Cell Receptor Antagonists and Env-Targeting Virus Inactivators.Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors.Immunogenetics: Genome-Wide Association of Non-Progressive HIV and Viral Load Control: HLA Genes and Beyond.Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.High glucose enhances HIV entry into T cells through upregulation of CXCR4.Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors.Anti-inflammatory interventions-what has worked, not worked, and what may work in the future.Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro.Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors Clinical relevance of target identity and biology: implications for drug discovery and development.Cytokine networking of innate immunity cells: a potential target of therapy.Chemokines, their receptors and human disease: the good, the bad and the itchy.CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV."Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.A Review of Functional Motifs Utilized by Viruses.Potential of small-molecule fungal metabolites in antiviral chemotherapy.Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.CCR5 as a treatment target in pulmonary arterial hypertension.Viral entry inhibition: too late for hepatitis C, but promising for other viral infections.Mechanisms of CNS Viral Seeding by HIV+ CD14+ CD16+ Monocytes: Establishment and Reseeding of Viral Reservoirs Contributing to HIV-Associated Neurocognitive Disorders.Antibody therapies for the prevention and treatment of viral infections.New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review.RING finger protein 113A regulates C-X-C chemokine receptor type 4 stability and signaling.Introduction to Lymphocyte Trafficking in Disease.Anti-retroviral drugs: current state and development in the next decade.Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate.

P2860

Q27755387-7B8EE18C-5EBA-455E-8E4D-2FA799573E20 Q28830304-9102675E-3678-414A-A666-1D8C6757A087 Q30352117-F9DA7D1A-CD4B-4EAA-B47D-6B8681FE76F6 Q30366071-FCD22B2A-CB80-4335-98BB-D98E1426540C Q30391222-97B263FC-EAA2-4EE9-8125-54B2D8667244 Q33613164-E6447B94-C5BA-478D-8928-B0780DEF2832 Q33690506-35B0FAA2-202A-463B-83D2-51766CFC824F Q34801630-94E6F281-C8F8-405E-91DF-72E9D07D4CDC Q35135565-97ADE0B4-D18A-4E7F-8F7D-4FCEE3520870 Q35600803-6FB11953-B050-4AF2-947A-1059E9471702 Q35685881-2337DF95-9415-4E9D-93BF-82D16A2F021D Q36003168-CDCF1FC2-AC4B-4564-9F01-816142C2DFEA Q36010083-2593426E-B532-4100-A081-CAF3104A8096 Q36406899-6C6F0A23-15C6-476C-BB17-C6B6CE71BD5B Q36681723-0F6D69B3-1D05-48C1-8086-0B460EA2D46B Q36876711-232BD607-7F3F-4FF7-8C74-C13D72E70BA0 Q37102101-0D65DF83-B12A-48F6-AB20-53E1EDA00939 Q37176327-33613B48-3734-4D6D-8F79-0576EEB79EF5 Q37286064-0E090B35-FD08-4D1B-905D-ADB2D64B60C3 Q37336472-0015A5BA-2925-45B3-A9B1-09FBDF9CEB4A Q37423972-CBA641AD-745F-46AB-98B1-91664C7F7AAF Q37596746-3746685F-D072-454B-A341-C072196DABBA Q38147723-6AAA1B34-8E9C-4B72-8F2F-6AAD8F1A689E Q38180799-41B1F4CB-B4E7-44B1-91A4-CBB593C074D3 Q38431506-12249978-49D5-4DED-AC6B-01F3B220C7DC Q38702121-626FD0DB-8155-497B-9BDA-96782AB3386A Q38803127-35051DEA-2D57-4826-ABB2-E125DB963406 Q39152233-6207F65D-42A4-412A-8AF7-841799584E00 Q39156048-BAB7F47B-F5FE-4103-8DB5-4D1DAC7C4FD9 Q39453829-568A4DE0-B175-4018-A0A1-C851FBFB561F Q41846910-E61E3555-4B3D-491A-B4C2-3DC7C5378F9E Q42020850-228EB011-F81E-43BE-8E5E-28CF0EA09E1D Q42201598-EA7A9C90-27F9-4A89-9194-B7549A6F4EE8 Q42638904-1F318CC0-9DD5-4E9C-B257-D8123D76E8FE Q47143843-C2F1CD8D-2471-40E3-AEEA-6842BDFFDEFE Q47296036-77A1FF8D-C188-477C-9ED2-731F506098A4 Q47697210-44783681-9952-4252-A5A3-8DDB965D02D2 Q52695639-20068BD9-396E-4424-AFF5-978A7892C6B1 Q54222874-DACB6AF1-F03D-407D-B0F8-75DF6DE75DBE Q55015745-A9314B01-E4D0-44A3-BDF4-42399ACE7BE0

P2860

HIV-1 entry inhibitors: recent development and clinical use

http://www.wikidata.org/entity/Q27003887

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

HIV-1 entry inhibitors: recent development and clinical use

@ast

HIV-1 entry inhibitors: recent development and clinical use

@en

HIV-1 entry inhibitors: recent development and clinical use

@nl

type

label

HIV-1 entry inhibitors: recent development and clinical use

@ast

HIV-1 entry inhibitors: recent development and clinical use

@en

HIV-1 entry inhibitors: recent development and clinical use

@nl

prefLabel

HIV-1 entry inhibitors: recent development and clinical use

@ast

HIV-1 entry inhibitors: recent development and clinical use

@en

HIV-1 entry inhibitors: recent development and clinical use

@nl

P1433

Q27003887-65F41190-0C54-4993-ACA9-A3823C4E9828

P1476

Q27003887-5BF74FBF-4E2E-45CE-8FDC-3D28219D1228

P2093

Q27003887-9B2352F1-0376-4295-8356-A9D84FF8669A

Q27003887-D136320D-02DB-41D4-8962-72A67DB23080

P2860

Q27003887-03CF0303-B4CC-407B-B6C3-69D2DA6538BC

Q27003887-0402A5BA-44E3-48DC-BB97-1C3FC06D6300

Q27003887-04B60F6D-6891-487C-8073-95A5239B1651

Q27003887-0A09759B-90C5-44D5-863E-9319339A281F

Q27003887-0A86F3AB-47DD-4EEA-8CA3-1F78E40C8795

Q27003887-1352B3E7-18C1-4D93-9B8B-7970AFEEF5AC

Q27003887-1B0B589C-BAC0-4C0D-A18D-376C35638014

Q27003887-20840D90-0BD9-4091-AD21-4F5D0DC42513

Q27003887-22781FEC-4527-4623-A385-159FC8D3CD7B

Q27003887-2A8A2ABF-DEC2-40DA-A10D-E51180A628F6

P304

Q27003887-3BDEC62F-3DC7-441E-9018-7A0DE0A40031

P31

Q27003887-8A292C5A-6EDE-4070-ACC4-8980FA8DB83F

P3181

Q27003887-342B7D08-E332-4531-AD9F-2395954F5E82

P356

Q27003887-F35B2792-485A-42E3-A3AD-8E782872F6B4

P407

Q27003887-9DDDEFFF-08BB-429D-ABEE-7CAF8C82AF01

P433

Q27003887-16E21A54-A6C8-49BB-953F-1BE8941AE9F0

P478

Q27003887-BF100BF0-FF6B-46B8-A7AE-8D24255F0A83

P577

Q27003887-5AB5FC9B-2F52-4258-8B8B-FDAD7A3CA8AE

P698

Q27003887-39DBC005-FF0D-4AF1-9928-331C3099D174

P932

Q27003887-8E53E86C-452A-41FB-99A3-AE8DB82C1EEF

P3181

P356

J.COVIRO.2012.12.002

P1433

Current opinion in virology

P1476

HIV-1 entry inhibitors: recent development and clinical use

@en

P2093

Daniel R Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Timothy J Henrich

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide

Core structure of gp41 from the HIV envelope glycoprotein

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

P304

51-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2107305

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.COVIRO.2012.12.002

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23290628

http://www.w3.org/2001/XMLSchema#string

P932

4213740

http://www.w3.org/2001/XMLSchema#string